Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Solid Biosciences Inc. (SLDB : NSDQ)

• Company Description    Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $0.54 Daily Weekly Monthly 20 Day Moving Average: 790,242 shares Shares Outstanding: 112.81 (millions) Market Capitalization: $61.08 (millions) Beta: 1.54 52 Week High: $4.92 52 Week Low: $0.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -41.79% -36.22% 12 Week -41.78% -36.83% Year To Date -69.06% -63.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 141 PORTLAND STREET FIFTH FLOOR - CAMBRIDGE,MA 02139 USA ph: 617-337-4680 fax: - None http://www.solidbio.com

• General Corporate Information    Officers Ilan Ganot - Chief Executive Officer; President and Director Ian F. Smith - Chairman of the Board Stephen DiPalma - Interim Chief Financial Officer Martin Freed - Director Robert Huffines - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83422E105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 112.81 Most Recent Split Date: (:1) Beta: 1.54 Market Capitalization: $61.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.33 Price/Cash Flow: - Price / Sales: 5.00 EPS Growth vs. Year Ago Period: -15.79% vs. Previous Quarter: -29.41% Sales Growth vs. Year Ago Period: -42.28% vs. Previous Quarter: -38.97% ROE 03/31/22 - -37.71 12/31/21 - -31.30 09/30/21 - -35.42 ROA 03/31/22 - -33.77 12/31/21 - -27.97 09/30/21 - -30.86 Current Ratio 03/31/22 - 9.13 12/31/21 - 9.43 09/30/21 - 10.59 Quick Ratio 03/31/22 - 9.13 12/31/21 - 9.43 09/30/21 - 10.59 Operating Margin 03/31/22 - -660.25 12/31/21 - -530.02 09/30/21 - - Net Margin 03/31/22 - -660.25 12/31/21 - -530.02 09/30/21 - - Pre-Tax Margin 03/31/22 - -660.25 12/31/21 - -530.02 09/30/21 - -716.04 Book Value 03/31/22 - 1.64 12/31/21 - 1.89 09/30/21 - 2.03 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.12 12/31/21 - 0.14 09/30/21 - 0.16

Powered by Zacks Investment Research ©